Why the study?
Cardiac involvement in familial partial lipodystrophy type 2 is increasingly recognized but remains less well characterized, particularly for LMNA variants outside the codon 482 hotspot and during metreleptin therapy.
Population
1 young woman with FPLD2, LMNA-related cardiomyopathy, and splice-site variant c.1488+1G>A
Design
Case report
Answers are grounded in this paper and cite their sources.
Severe cardiac deterioration despite metabolic improvement in LMNA-FPLD2 warrants close cardiac monitoring on metreleptin; leaves open whether therapy influences cardiomyopathy progression.
Familial partial lipodystrophy type 2 (FPLD2) is a rare autosomal dominant laminopathy caused by variants in the LMNA gene and characterized by progressive loss of subcutaneous adipose tissue and metabolic complications. Cardiac involvement is increasingly recognized but remains less well characterized, particularly for variants outside the codon 482 hotspot. We report this case as it demonstrates the natural course of LMNA-associated cardiomyopathy during metreleptin therapy in a young patient with a rare splice-site variant (c.1488+1G>A). Her clinical presentation included acanthosis nigricans, hirsutism, muscular hypertrophy of the extremities, and marked lipoatrophy. The patient’s medical history included metabolic dysfunction-associated steatotic liver disease (MASLD), diagnosed at age 12, as well as an ischemic stroke at age 17. Conduction disease and ventricular tachyarrhythmias led to implantation of a dual-chamber implantable cardioverter-defibrillator (ICD) in April 2022, and left ventricular ejection fraction (LVEF) declined from 59% to 45-48% within the same year. Metreleptin (2.0 mg/day) was started in November 2023, after genetic confirmation. During approximately 10 months of treatment, insulin and transaminase levels decreased, although weight loss related to advanced chronic heart failure (CHF) and concomitant therapy limit the interpretation of these changes. Cardiac disease progressed: by September 2024, LVEF had fallen to 14.3%, and the device was upgraded to left bundle branch area pacing with defibrillator (LBBAP-ICD). After discharge, the patient developed bilateral pneumonia with respiratory failure and recurrent decompensation of CHF, and she died in November 2024, at the age of 19. To our knowledge, this is the first report of metreleptin use in an adult with FPLD2 in Kazakhstan.
No takes yet. Share an insight, caveat, or question.
Alzhaxina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: